BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laupèze B, Hervé C, Di Pasquale A, Tavares Da Silva F. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. Vaccine 2019;37:5670-80. [PMID: 31420171 DOI: 10.1016/j.vaccine.2019.07.098] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Zhao Y, Li Y, Chen X. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines (Basel) 2021;9:75. [PMID: 33494477 DOI: 10.3390/vaccines9020075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Nam HJ, Hong SJ, Lee A, Kim J, Lee S, Casper C, Carter D, Reed SG, Simeon G, Shin EC. An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21. NPJ Vaccines 2022;7:45. [PMID: 35459225 DOI: 10.1038/s41541-022-00467-z] [Reference Citation Analysis]
3 Zhalimov V, Gritsyna Y, Morenkov O. The effect of apolipoprotein A-I and perfluorocarbon emulsion on the production of specific antibodies in mice. Clin Exp Vaccine Res 2021;10:259-63. [PMID: 34703809 DOI: 10.7774/cevr.2021.10.3.259] [Reference Citation Analysis]
4 Yang J, Tseng J, Yu G, Luo Y, Huang CF, Hong Y, Chuang T. Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases. Pharmaceutics 2022;14:423. [DOI: 10.3390/pharmaceutics14020423] [Reference Citation Analysis]
5 Liu G, Zhu M, Zhao X, Nie G. Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. Adv Drug Deliv Rev 2021;176:113889. [PMID: 34364931 DOI: 10.1016/j.addr.2021.113889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
6 O'Hagan DT, van der Most R, Lodaya RN, Coccia M, Lofano G. "World in motion" - emulsion adjuvants rising to meet the pandemic challenges. NPJ Vaccines 2021;6:158. [PMID: 34934069 DOI: 10.1038/s41541-021-00418-0] [Reference Citation Analysis]
7 Misra RS, Nayak JL. The Importance of Vaccinating Children and Pregnant Women against Influenza Virus Infection. Pathogens 2019;8:E265. [PMID: 31779153 DOI: 10.3390/pathogens8040265] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kim YH, Hong KJ, Kim H, Nam JH. Influenza vaccines: Past, present, and future. Rev Med Virol 2021;:e2243. [PMID: 33949021 DOI: 10.1002/rmv.2243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Andreas S, Testa M, Boyer L, Brusselle G, Janssens W, Kerwin E, Papi A, Pek B, Puente-maestu L, Saralaya D, Watz H, Wilkinson TMA, Casula D, Di Maro G, Lattanzi M, Moraschini L, Schoonbroodt S, Tasciotti A, Arora AK, Maltais F, Brusselle G, Corhay J, Janssens E, Janssens W, Leys M, Ferguson M, Fitzgerald M, Maltais F, Mayers I, Mcneil S, Pek B, Bourdin A, Boyer L, Couturaud F, Dussart L, Andreas S, Illies G, Eich A, Ludwig-sengpiel A, Watz H, Blasi F, Centanni S, Papi A, Pomari C, Echave-sustaeta JM, Llorca Martínez E, Narejos Pérez S, Pascual-guardia S, Pérez Vera M, Puente-maestu L, Terns Riera M, Anderson W, Choudhury G, De-soyza A, Saralaya D, Wilkinson TM, Boscia Iii J, Chinsky K, Dunn L, Erb D, Fogarty C, Downey HJ, Kerwin E, Kunz C, Poling T, Sellman R, Sigal B, Southard J, Spangenthal S, Tannous Z, Testa M, Casula D, Di Maro G, Lattanzi M, Moraschini L, Schoonbroodt S, Tasciotti A, Arora AK. Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. The Lancet Respiratory Medicine 2022;10:435-46. [DOI: 10.1016/s2213-2600(21)00502-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Dai M, Feng X, Mo Z, Sun Y, Fu L, Zhang Y, Wu J, Yu B, Zhang H, Yu X, Wu H, Kong W. Stimulation Effects and Mechanisms of Different Adjuvants on a Norovirus P Particle-Based Active Amyloid-β Vaccine. J Alzheimers Dis 2020;77:1717-32. [PMID: 32925038 DOI: 10.3233/JAD-200351] [Reference Citation Analysis]
12 Saito T, Sako Y, Sato-Kaneko F, Hosoya T, Yao S, Lao FS, Shpigelman J, Messer K, Pu M, Shukla NM, Chan M, Chu PJ, Cottam HB, Hayashi T, Carson DA, Corr M. Small Molecule Potentiator of Adjuvant Activity Enhancing Survival to Influenza Viral Challenge. Front Immunol 2021;12:701445. [PMID: 34650551 DOI: 10.3389/fimmu.2021.701445] [Reference Citation Analysis]
13 Raoufi E, Bahramimeimandi B, Salehi-Shadkami M, Chaosri P, Mozafari MR. Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review. Biomedicines 2021;9:520. [PMID: 34066608 DOI: 10.3390/biomedicines9050520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sasaki E, Hamaguchi I, Mizukami T. Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design. Expert Opin Drug Metab Toxicol 2020;16:1051-61. [PMID: 32772723 DOI: 10.1080/17425255.2020.1807936] [Reference Citation Analysis]
15 Allahyari M, Golkar M, Fard-Esfahani P, Dimier-Poisson I, Mévélec MN. Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis. Microb Pathog 2021;162:105312. [PMID: 34826553 DOI: 10.1016/j.micpath.2021.105312] [Reference Citation Analysis]
16 Bi D, Apter D, Eriksson T, Hokkanen M, Zima J, Damaso S, Soila M, Dubin G, Lehtinen M, Struyf F. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years. Hum Vaccin Immunother 2020;16:1392-403. [PMID: 31829767 DOI: 10.1080/21645515.2019.1692557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Nanishi E, Dowling DJ, Levy O. Toward precision adjuvants: optimizing science and safety. Curr Opin Pediatr 2020;32:125-38. [PMID: 31904601 DOI: 10.1097/MOP.0000000000000868] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 12.5] [Reference Citation Analysis]
18 Heath MD, Mohsen MO, de Kam PJ, Carreno Velazquez TL, Hewings SJ, Kramer MF, Kündig TM, Bachmann MF, Skinner MA. Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®). Front Immunol 2020;11:594911. [PMID: 33324411 DOI: 10.3389/fimmu.2020.594911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kheirollahpour M, Mehrabi M, Dounighi NM, Mohammadi M, Masoudi A. Nanoparticles and Vaccine Development. Pharm Nanotechnol 2020;8:6-21. [PMID: 31647394 DOI: 10.2174/2211738507666191024162042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
20 Rosini R, Nicchi S, Pizza M, Rappuoli R. Vaccines Against Antimicrobial Resistance. Front Immunol 2020;11:1048. [PMID: 32582169 DOI: 10.3389/fimmu.2020.01048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
21 Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, Cunningham AL. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother 2020;16:2628-33. [PMID: 32347767 DOI: 10.1080/21645515.2020.1741312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ley K. Role of the adaptive immune system in atherosclerosis. Biochem Soc Trans 2020;48:2273-81. [PMID: 32869829 DOI: 10.1042/BST20200602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]